The HCPLive Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.
January 30th 2023
The specific mechanisms involved in associations between air pollution and respiratory illness without viral infection are not understood, especially compared with those of respiratory viruses and asthma exacerbation.
E-cigarettes are marketed as an alternative to tobacco, though discussion within the research community emphasizes the inconsistencies in evidence regarding health and addiction among users.
Despite its frequent use as a rescue therapy for patients with interstitial lung disease associated with connective tissue disorder, the effectiveness of rituximab hasn't been evaluated in many clinical trials.
"Especially when untreated and in late stages of progression, ILD is well known to impact health related quality of life," according to Dr. Briana DiSilvio. "Chronic dyspnea, cough, and reduced exercise capacity can become disabling."
Patients with pulmonary tuberculosis (TB) exhibited an improvement in quality of life and a reduction in treatment costs by utilizing a digital medication event reminder monitor (MERM).
Novel insights into the risk-benefit profile of nintedanib in children and adolescents with fibrosing interstitial lung disease (ILD) were provided by late-breaking data presented at ERS 2022 regarding the InPedILD clinical trial.
Late-breaking data presented at ERS Congress 2022 show that inhaler sensors and mobile health (mHealth) applications combined with pharmacist counseling improved treatment adherence for patients with uncontrolled asthma.
These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.
“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.